To our knowledge, this is the first documented case of emergent KRASG12D and NF1L1083R aberration concurrently occurring with primary BRAF V600E altered glioblastoma as an acquired mechanism of resistance in the setting of BRAF and MEK inhibition leading to morphological transformation to gliosarcoma. The gene discussed is MAP2K7; the disease is glioblastoma.